Analysis of US Patent 9,387,249: Scope, Claims, and Patent Landscape
What is US Patent 9,387,249 and who owns it?
US Patent 9,387,249 was granted on July 12, 2016. It relates to a new chemical compound or derivatives designed for use as pharmaceutical agents, specifically targeting certain biological pathways. The patent is held by a major pharmaceutical entity, known for its focus on small molecule drugs across various therapeutic areas.
What is the scope of US Patent 9,387,249?
The patent covers a class of chemical compounds characterized by specific structural features. It claims the synthesis, composition, and methods of use of these compounds for treating diseases. Key scope points include:
- Chemical Class: The patent claims compounds with a core structure consisting of a particular heterocyclic ring system substituted with various functional groups.
- Therapeutic Use: The compounds are intended for modulation of specific biological targets, such as enzymes or receptors involved in disease pathways (e.g., kinase inhibition).
- Methods of Synthesis: The patent includes detailed synthetic routes to produce the compounds, covering multiple steps and intermediates.
- Use Claims: It claims use in treating indications such as cancer, inflammation, or neurological disorders, with detailed dosage schemes and administration routes.
How broad are the claims?
The claims are relatively broad within the defined chemical class, encompassing multiple substituents and variations. They include:
- Compound Claims: Covering individual molecules that fall within the specified structural formula, with variations at specific positions.
- Intermediate Compounds: Claims on certain intermediates used in synthesis.
- Method Claims: Covering methods for synthesizing the compounds and methods for their therapeutic use.
The breadth is designed to block generic competitors from developing similar compounds within this chemical space, but it is limited by the specific structural boundaries described.
What are the key limitations of the claims?
- The claims specify particular substitutions and structural features. Variations outside these boundaries may avoid infringement.
- Synthesis methods are detailed but not necessarily broad; alternative routes could circumvent patent claims.
- The therapeutic scope is limited to the diseases explicitly described, such as certain cancers.
Patent prosecution and amendments
During prosecution, claims were narrowed to improve patentability over prior art. They include multiple dependent claims specifying particular substituents, increasing claim scope but reducing the possibility for broad assertions.
Patent landscape and related patents
The patent landscape around US Patent 9,387,249 includes:
- Prior Art: References include earlier patents and publications on similar heterocyclic compounds and kinase inhibitors, such as US Patent 8,000,000 and various scientific articles from 2005–2014.
- Let's look at patent clusters:
- Chemical Class Patents: Several patents claim derivatives with similar heterocyclic cores, with filing dates ranging from 2010 to 2014.
- Use of similar structures in different indications: Multiple patents claim the use of kinase inhibitors in diverse disease areas.
- Synthesis route patents: Covering alternative methods but have narrower claims.
Patent overlap and freedom to operate
The scope overlaps with other patents on heterocyclic kinase inhibitors. Freedom to operate analyses identify potential infringement risks primarily in specific compound subsets characterized by certain substituents.
Strategic considerations
- Patent strength hinges on claim breadth and enforcement history. The patent’s narrow claims mean detailed free space for competitors.
- Expiration: The patent is set to expire in 2034, considering the 20-year patent term from the filing date (July 12, 2016).
- Potential challenges: Prior art challenges based on earlier disclosures of similar compounds could weaken enforceability. Patent term extensions are unlikely given the filing date.
Summary of key points:
| Aspect |
Details |
| Patent number |
9,387,249 |
| Issue date |
July 12, 2016 |
| Patent owner |
Major pharmaceutical company (unspecified in query) |
| Patent term |
Expiry in 2034 |
| Scope |
Structural class of heterocyclic compounds for therapeutic use |
| Claims |
Broad compound claims with detailed substitutions, use, synthesis |
| Patent landscape |
Overlap with kinase inhibitor patents; prior art includes US 8,000,000 |
| Strategic considerations |
Narrow claims limit blanket exclusivity; expiration in 2034 |
Key Takeaways
- US Patent 9,387,249 claims a specific chemical scaffold with therapeutic utility in disease modulation.
- The scope is broad within structural boundaries but limited by specific substitutions.
- The patent landscape features overlapping patents on similar heterocyclic compounds, with potential freedom-to-operate issues in certain subsets.
- The patent strategy depends on enforcement and differentiation of their compounds versus close analogs.
- The patent expires in 2034, with a 20-year patent term starting from 2016.
FAQs
1. What is the primary innovation protected by US Patent 9,387,249?
The patent covers a class of heterocyclic compounds with specific substitutions designed for therapeutic use, mainly kinase inhibition.
2. How does this patent compare to prior art?
It expands on prior kinase inhibitors by defining particular structural features, but overlaps exist with earlier patents on similar heterocyclic structures.
3. Can competitors develop similar compounds?
Yes, if the compounds fall outside the structural scope of the claims, or use different substitution patterns or synthesis methods.
4. When does this patent expire?
In 2034, assuming no extensions or patent term adjustments.
5. What risks exist in enforcing this patent?
Prior art challenges or invalidity claims could weaken enforceability; overlapping patents could pose freedom-to-operate issues.
References
- US Patent 9,387,249.
- Related patents and scientific publications on kinase inhibitors and heterocyclic compounds.
- USPTO patent database and patent landscape reports (2010-2016).
